{"id":394132,"date":"2020-12-07T07:42:39","date_gmt":"2020-12-07T12:42:39","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=394132"},"modified":"2020-12-07T07:42:39","modified_gmt":"2020-12-07T12:42:39","slug":"olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/","title":{"rendered":"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN FRANCISCO, Dec.  07, 2020  (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020.<\/p>\n<p>The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1\/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor (HR)-positive, human epidermal growth factor receptor 2 negative (HER2-) breast cancer.<\/p>\n<p>The accepted abstracts are now available online through the SABCS conference website. Details are as follows:<\/p>\n<p>\n        <strong>Olema Poster Presentations<\/strong>\n      <\/p>\n<p>Session: 18 \u2013 Tumor Biology III<br \/>Poster #: PS18-16<br \/>Abstract #: 1410<br \/>Title: The Complete Estrogen Receptor Antagonist OP-1250 Shrinks Tumors in Xenograft Models and Has Favorable Preclinical Pharmacokinetic Attributes<br \/>Session Date &amp; Time: Wednesday, December 9, 2020; 8:00 a.m. CT<\/p>\n<p>Session: Ongoing Trials \u2013 Endocrine Therapy<br \/>Poster #: OT-09-10<br \/>Abstract #: 1167<br \/>Title: A Phase I\/II Open-label, First-in-Human, Multicenter, Dose Escalation and Dose Expansion Study of OP-1250 Monotherapy in Adult Subjects<br \/>with Locally Advanced, Recurrent, and Metastatic Hormone Receptor (HR)-Positive, HER2-Negative Breast Cancer <br \/>Session Date &amp; Time: Wednesday, December 9, 2020; 8:00 a.m. CT<\/p>\n<p>\n        <strong>About Olema Oncology<\/strong><br \/>\n        <br \/>Olema Oncology is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers. Olema\u2019s lead product candidate, OP-1250, is an orally available small molecule with combined activity as both a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is currently being evaluated as a single agent in an ongoing Phase 1\/2 clinical trial in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer. Olema is headquartered in San Francisco.<\/p>\n<p>\n        <strong>Forward Looking Statements<\/strong><br \/>\n        \n      <\/p>\n<p>Statements contained in this press release regarding matters that are not historical facts are \u201cforward-looking statements\u201d within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as \u201cbelieve,\u201d \u201canticipate,\u201d \u201cplan,\u201d \u201cexpect,\u201d \u201cintend,\u201d \u201cwill,\u201d \u201cmay,\u201d \u201cgoal,\u201d \u201cproject,\u201d \u201cestimate,\u201d \u201cpotential\u201d and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These statements include those related to the potential safety, functional characteristics and efficacy of OP-1250; and Olema\u2019s ability to successfully advance, and the potential timelines for, the development of OP-1250. Because such statements deal with future events and are based on Olema\u2019s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of Olema could differ materially from those described in or implied by the statements in this press release. These forward-looking statements are subject to risks and uncertainties, including, without limitation, the risk that Olema\u2019s ongoing or future clinical studies in humans may show that OP-1250 is not a tolerable and effective treatment for breast cancer and other risks and uncertainties affecting Olema, as well as those discussed in the sections titled \u201cRisk Factors\u201d in Olema\u2019s prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, on November 19, 2020, and future filings and reports that Olema makes from time to time with the United States Securities and Exchange Commission. Except as required by law, Olema assumes no obligation to update these forward-looking statements or to update the reasons if actual results differ materially from those anticipated in the forward-looking statements.<\/p>\n<p>\n        <strong>Contacts<\/strong><br \/>\n        <br \/>Investor Contact:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bb5Hia5GZ0pud301wrQYd3EBDxSaOXNsxm8qqAcIa9pAiKmEePiV1hWXeYvQhpf6cMDEjkQoURI17KnovBktBg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">ir@olema.com<\/a>\u00a0<\/p>\n<p>Media Contact:<br \/>Sheryl Seapy, W2O<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WKP6KbG-nOLqsUwRb3ZJldhGdHlaE55cTMi8KwDQ0NKh9divfe5lIqpyCu-_RqMKAj_OO1yhr6JgvBO8eKguABCWUs5jrSuseYHQEvdssmQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">sseapy@w2ogroup.com<\/a>\u00a0<br \/>949-903-4750<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/4cb77b9d-e729-44f7-928c-b74a5a932d85\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020. The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1\/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor (HR)-positive, human epidermal growth &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-394132","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020. The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1\/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor (HR)-positive, human epidermal growth &hellip; Continue reading &quot;Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-07T12:42:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020\",\"datePublished\":\"2020-12-07T12:42:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/\"},\"wordCount\":631,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/\",\"name\":\"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=\",\"datePublished\":\"2020-12-07T12:42:39+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/","og_locale":"en_US","og_type":"article","og_title":"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 - Market Newsdesk","og_description":"SAN FRANCISCO, Dec. 07, 2020 (GLOBE NEWSWIRE) &#8212; Olema Pharmaceuticals, Inc. (\u201cOlema\u201d or \u201cOlema Oncology\u201d), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women\u2019s cancers, today announced two posters relating to OP-1250, a complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), will be presented at the San Antonio Breast Cancer Symposium (SABCS), to be held virtually from December 8-11, 2020. The accepted abstracts cover a preclinical study evaluating the effects of OP-1250 in xenograft models and the protocol for a Phase 1\/2 open-label, first-in-human, multicenter, dose escalation and dose expansion study evaluating OP-1250 monotherapy in adult subjects with locally advanced, recurrent, and metastatic Hormone Receptor (HR)-positive, human epidermal growth &hellip; Continue reading \"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-07T12:42:39+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020","datePublished":"2020-12-07T12:42:39+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/"},"wordCount":631,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/","name":"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=","datePublished":"2020-12-07T12:42:39+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5NzgxNCMzODU5MzQzIzIyMDM1MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/olema-oncology-announces-two-poster-presentations-at-the-san-antonio-breast-cancer-symposium-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Olema Oncology Announces Two Poster Presentations at the San Antonio Breast Cancer Symposium 2020"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394132","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=394132"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/394132\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=394132"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=394132"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=394132"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}